Sicart Associates’s 10x Genomics TXG Stock Holding History

Sicart Associates’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,650	Closed	-$234K	–	125
2020 Q4	$234K	Buy	+1,650	New	+$239K	0.06%	100

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sicart Associates's TXG Position: Q1 2021 in Review

Sicart Associates sold out of 10x Genomics (TXG) in Q1 2021, closing a stake of 1,650 shares — an estimated $234K sold.

Sicart Associates first reported a position in TXG in Q4 2020 and held it in 1 quarter. The position peaked at $234K in Q4 2020. 324 funds tracked by Wall St. Rank hold TXG as of Q1 2021.

Sicart Associates reported no remaining 10x Genomics position as of Q1 2021 after selling out during the quarter.
Sicart Associates sold 1,650 10x Genomics shares in Q1 2021, an estimated $234K.
Sicart Associates first reported a position in 10x Genomics in Q4 2020 and held it in 1 quarter.
Sicart Associates's 10x Genomics position peaked at $234K in Q4 2020.
324 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2021.

Based on Sicart Associates's 13F filing for Q1 2021, filed 10 May 2021.